Cited by 4,792Nanoparticle-Based Drug DeliveryUltrasound and Hyperthermia ApplicationsRNA Interference and Gene Delivery

The DOI matches its Crossref record; 127 of the 140 references it cites were found in a registry or an index.

Doxil® — The first FDA-approved nano-drug: Lessons learned

Barenholz, Yechezkel (Chezy)·2012·Journal of Controlled Release

DOI 10.1016/j.jconrel.2012.03.020

Open this paper in CoChat — free account

Abstract

Doxil®, the first FDA-approved nano-drug (1995), is based on three unrelated principles: (i) prolonged drug circulation time and avoidance of the RES due to the use of PEGylated nano-liposomes; (ii) high and stable remote loading of doxorubicin driven by a transmembrane ammonium sulfate gradient, which also allows for drug release at the tumor; and (iii) having the liposome lipid bilayer in a "liquid ordered" phase composed of the high-T(m) (53 °C) phosphatidylcholine, and cholesterol. Due to the EPR effect, Doxil is "passively targeted" to tumors and its doxorubicin is released and becomes available to tumor cells by as yet unknown means. This review summarizes historical and scientific perspectives of Doxil development and lessons learned from its development and 20 years of its use. It demonstrates the obligatory need for applying an understanding of the cross talk between physicochemical, nano-technological, and biological principles. However, in spite of the large reward, ~2 years after Doxil-related patents expired, there is still no FDA-approved generic "Doxil" available.

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2012.03.020

Cites

127 of 127 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,868
PEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,344
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,030
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Pharmacokinetics of Pegylated Liposomal Doxorubicin
Gabizón, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,639
Self-citation
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Self-citation
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,357
Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase.
Abuchowski, A., McCoy, J. R., Palczuk, N. C., Es, T. V., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,276
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
Gordon, A. N., Fleagle, J., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, Á. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,212

Flagged first, then by citations

Show all 140 references

13 of the 140 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

Amselem, 1993, A large-scale method for the preparation of sterile and nonpyrogenic liposomal formulations of defined size distributions for clinical use, vol. 1, 501
Barenholz, 1993, Quality control assays in the development and clinical use of liposome-based formulations, vol. 1, 527
Poste, 1983, Liposome targeting in vivo: problems and opportunities, Biol. Cell, 47, 19

Sorted by citations

Items 401–500 of 1,008

Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization
Makwana, V., Karanjia, J., Haselhorst, T., Anoopkumar‐Dukie, S., & Rudrawar, S. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120117 · Cited by 142
The Phospholipid Research Center: Current Research in Phospholipids and Their Use in Drug Delivery
Drescher, S., & van Hoogevest, P. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121235 · Cited by 157
Asymmetric Flow Field-Flow Fractionation in the Field of Nanomedicine
Wagner, M., Holzschuh, S., Traeger, A., Fahr, A., & Schubert, U. S. (2014) · Analytical Chemistry · doi:10.1021/ac501664t · Cited by 141
Building nanostructures with drugs
Ma, W., Cheetham, A. G., & Cui, H. (2016) · Nano Today · doi:10.1016/j.nantod.2015.11.003 · Cited by 140
Transforming Medicine: Cutting-Edge Applications of Nanoscale Materials in Drug Delivery
Tenchov, R., Hughes, K. J., Ganesan, M., Iyer, K. A., Ralhan, K., Diaz, L. M. L., Bird, R. E., Ivanov, J. M., & Zhou, Q. A. (2025) · ACS Nano · doi:10.1021/acsnano.4c09566 · Cited by 153
Rational Design of Polyion Complex Nanoparticles to Overcome Cisplatin Resistance in Cancer Therapy
Yang, X., Du, X., Liu, Y., Zhu, Y., Liu, Y., Li, Y., & Wang, J. (2013) · Advanced Materials · doi:10.1002/adma.201303360 · Cited by 140
Dispersion of Nanoparticles in Different Media Importantly Determines the Composition of Their Protein Corona
Strojan, K., Leonardi, A., Bregar, V. B., Križaj, I., Svete, J., & Pavlin, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169552 · Cited by 146
Applications of nanoscale metal–organic frameworks as imaging agents in biology and medicine
Duman, F. D., & Forgan, R. S. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb00358e · Cited by 143
An overview of nanotoxicity and nanomedicine research: principles, progress and implications for cancer therapy
Wang, Y., Santos, A., Evdokiou, A., & Lošić, D. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb00956a · Cited by 140
Engineering Polymersomes for Diagnostics and Therapy
Leong, J., Teo, J. Y., Aakalu, V. K., Yang, Y. Y., & Kong, H. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701276 · Cited by 145
Dual function luminescent transition metal complexes for cancer theranostics: The combination of diagnosis and therapy
Ko, C.-N., Li, G., Leung, C., & Ma, D. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.11.013 · Cited by 139
Biodegradable Inorganic Nanoparticles for Cancer Theranostics: Insights into the Degradation Behavior
Zhou, H., Ge, J., Miao, Q., Zhu, R., Wen, L., Zeng, J., & Gao, M. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00699 · Cited by 141
Active Transportation of Liposome Enhances Tumor Accumulation, Penetration, and Therapeutic Efficacy
Wang, G., Wu, B., Li, Q., Chen, S., Jin, X., Liu, Y., Zhou, Z., Shen, Y., & Huang, P. (2020) · Small · doi:10.1002/smll.202004172 · Cited by 138
Overcoming Physiological Barriers to Nanoparticle Delivery—Are We There Yet?
Thomas, O. S., & Weber, W. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00415 · Cited by 146
A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives
Shi, Y., Lu, A., Wang, X., Belhadj, Z., Wang, J., & Zhang, Q. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.002 · Cited by 144
Biomedical Applications of Plant Extract-Synthesized Silver Nanoparticles
Simon, S., Sibuyi, N. R. S., Fadaka, A. O., Meyer, S., Josephs, J., Onani, M. O., Meyer, M., & Madiehe, A. M. (2022) · Biomedicines · doi:10.3390/biomedicines10112792 · Cited by 145
Diffusion-Limited Processes in Hydrogels with Chosen Applications from Drug Delivery to Electronic Components
Lavrentev, F. V., Shilovskikh, V. V., Alabusheva, V. S., Yurova, V. Y., Nikitina, A. A., Ulasevich, S. A., & Скорб, Е. В. (2023) · Molecules · doi:10.3390/molecules28155931 · Cited by 138
PEGylated nanomedicines: recent progress and remaining concerns
Vllasaliu, D., Fowler, R., & Stolnik, S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.866651 · Cited by 137
An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance
Liao, Z., Chuang, E., Lin, C.-C., Ho, Y., Lin, K., Cheng, P., Chen, K., Wei, H.-J., & Sung, H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.032 · Cited by 137
Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy
Xiao, B., Ma, L., & Merlin, D. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1205583 · Cited by 139
The Use of Nanoparticulates to Treat Breast Cancer
Tang, X., Loc, W. S., Dong, C., Matters, G. L., Butler, P. J., KESTER, M. A., Meyers, C., Jiang, Y., & Adair, J. H. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0202 · Cited by 146
Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy
Guimarães, P. P. G., Gaglione, S. A., Sewastianik, T., Carrasco, R. D., Langer, R., & Mitchell, M. J. (2018) · ACS Nano · doi:10.1021/acsnano.7b05876 · Cited by 139
Nanocarriers: A Successful Tool to Increase Solubility, Stability and Optimise Bioefficacy of Natural Constituents
Bilia, A. R., Piazzini, V., Risaliti, L., Vanti, G., Casamonti, M., Wang, M., & Bergonzi, M. C. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181101110050 · Cited by 152
The past, present, and future of breast cancer models for nanomedicine development
Boix-Montesinos, P., Soriano‐Teruel, P. M., Armiñán, A., Orzáez, M., & Vicent, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.018 · Cited by 146
Microfluidic synthesis of lipid-based nanoparticles for drug delivery: recent advances and opportunities
Mehraji, S., & DeVoe, D. L. (2024) · Lab on a Chip · doi:10.1039/d3lc00821e · Cited by 144
Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG–PE micelles in ovarian cancer cell spheroid model
Perche, F., Patel, N. R., & Torchilin, V. P. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.003 · Cited by 136
Dual-functional drug liposomes in treatment of resistant cancers
Mu, L.-M., Ju, R.-J., Liu, R., Bu, Y.-Z., Zhang, J., Li, X., Zeng, F., & Lü, W.-L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.006 · Cited by 136
Recent Progress in the Theranostics Application of Nanomedicine in Lung Cancer
Mukherjee, A., Paul, M. K., & Mukherjee, S. (2019) · Cancers · doi:10.3390/cancers11050597 · Cited by 138
ROS-responsive nanoparticles based on amphiphilic hyperbranched polyphosphoester for drug delivery: Light-triggered size-reducing and enhanced tumor penetration
Jin, H., Zhu, T., Huang, X., Sun, M., Li, H., Zhu, X., Liu, M., Xie, Y., Huang, W., & Yan, D. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.04.029 · Cited by 135
Emerging Trends in Micro- and Nanoscale Technologies in Medicine: From Basic Discoveries to Translation
Álvarez, M. M., Aizenberg, J., Analoui, M., Andrews, A. M., Bisker, G., Boyden, E. S., Kamm, R. D., Karp, J. M., Mooney, D. J., Öklü, R., et al. (2017) · ACS Nano · doi:10.1021/acsnano.7b01493 · Cited by 137
Ligation Strategies for Targeting Liposomal Nanocarriers
Marqués‐Gallego, P., & de Kroon, A. I. P. M. (2014) · BioMed Research International · doi:10.1155/2014/129458 · Cited by 135
The potential anti‐infective applications of metal oxide nanoparticles: A systematic review
Abo‐zeid, Y., & Williams, G. R. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1592 · Cited by 140
Recent advances in drug delivery systems for enhancing drug penetration into tumors
He, B., Sui, X., Yu, B., Wang, S., Shen, Y., & Cong, H. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1831106 · Cited by 143
Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy
Zhao, Y., Fay, F., Hak, S., Perez‐Aguilar, J. M., Sánchez-Gaytán, B. L., Brandon, G., Duivenvoorden, R., Davies, C. D. L., Bjørkøy, A., Weinstein, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms11221 · Cited by 136
Charge-Reversal APTES-Modified Mesoporous Silica Nanoparticles with High Drug Loading and Release Controllability
Wang, Y., Sun, Y., Wang, J., Yang, Y., Li, Y., Yuan, Y., & Liu, C. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b05370 · Cited by 134
Nanomedicine-mediated cancer stem cell therapy
Shen, S., Xia, J., & Wang, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.09.037 · Cited by 132
Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic
Au, K. M., Satterlee, A., Min, Y., Tian, X., Kim, Y. S., Caster, J. M., Zhang, L., Zhang, T., Huang, L., & Wang, A. Z. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.018 · Cited by 134
Ultrasmall-in-Nano Approach: Enabling the Translation of Metal Nanomaterials to Clinics
Cassano, D., Pocoví‐Martínez, S., & Voliani, V. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00664 · Cited by 134
Transforming nanomedicine manufacturing toward Quality by Design and microfluidics
Colombo, S., Beck‐Broichsitter, M., Boetker, J. P., Malmsten, M., Rantanen, J., & Bohr, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.004 · Cited by 141
Aggregation-induced emission (AIE) fluorophores as imaging tools to trace the biological fate of nano-based drug delivery systems
Wang, Y., Zhang, Y., Wang, J., & Liang, X. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.12.004 · Cited by 132
Development of functional liposomes by modification of stimuli-responsive materials and their biomedical applications
Yuba, E. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02470k · Cited by 134
An updated review of folate-functionalized nanocarriers: A promising ligand in cancer
Ebrahimnejad, P., Sodagar Taleghani, A., Asare-Addo, K., & Nokhodchi, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2021.11.011 · Cited by 133
Nanocrystals for the parenteral delivery of poorly water-soluble drugs
Sun, B., & Yeo, Y. (2012) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2012.10.004 · Cited by 132
Quantitative Analysis of the Enhanced Permeation and Retention (EPR) Effect
Wong, A. D., Ye, M., Ulmschneider, M. B., & Searson, P. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123461 · Cited by 137
Self-assembled mirror DNA nanostructures for tumor-specific delivery of anticancer drugs
Kim, K., Kim, H. Y., Lee, Y.-D., Ha, J. S., Kang, J. H., Jeong, H., Bang, D., Ko, Y. T., Kim, S., Lee, H., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.10.015 · Cited by 132
Microfluidic technologies for nanoparticle formation
Tian, F., Cai, L., Liu, C., & Sun, J. (2021) · Lab on a Chip · doi:10.1039/d1lc00812a · Cited by 132
Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials
Krasteva, N. A., & Georgieva, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061213 · Cited by 148
Are Existing Standard Methods Suitable for the Evaluation of Nanomedicines: Some Case Studies
Gioria, S., Caputo, F., Urbán, P., Maguire, C. M., Bremer‐Hoffmann, S., Prina‐Mello, A., Calzolai, L., & Méhn, D. (2018) · Nanomedicine · doi:10.2217/nnm-2017-0338 · Cited by 137
Organ‐on‐a‐Chip: A Preclinical Microfluidic Platform for the Progress of Nanomedicine
Rodrigues, R. O., Sousa, P. C., Gaspar, J., Bañobre‐López, M., Lima, R. A., & Minas, G. M. H. (2020) · Small · doi:10.1002/smll.202003517 · Cited by 134
Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation
González‐Valdivieso, J., Girotti, A., Schneider, J., & Arias, F. J. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120438 · Cited by 138
Delivery of cancer therapies by synthetic and bio-inspired nanovectors
Briolay, T., Petithomme, T., Fouet, M., Nguyen-Pham, N., Blanquart, C., & Boisgerault, N. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01346-2 · Cited by 142
Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics
Ewert, K. K., Scodeller, P., Simón‐Gracia, L., Steffes, V. M., Wonder, E. A., Teesalu, T., & Safinya, C. R. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091365 · Cited by 128
Liposome and Their Applications in Cancer Therapy
Pandey, H., Rani, R., & Agarwal, V. K. (2016) · Brazilian Archives of Biology and Technology · doi:10.1590/1678-4324-2016150477 · Cited by 132
Particle Targeting in Complex Biological Media
Dai, Q., Bertleff‐Zieschang, N., Braunger, J. A., Björnmalm, M., Cortez‐Jugo, C., & Caruso, F. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700575 · Cited by 132
Nano-delivery to the lung - by inhalation or other routes and why nano when micro is largely sufficient?
Forest, V., & Pourchez, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114173 · Cited by 135
Lipid carriers for mRNA delivery
Zhang, W., Jiang, Y., He, Y., Boucetta, H., Wu, J., Chen, Z., & He, W. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.026 · Cited by 134
Nanobowl-Supported Liposomes Improve Drug Loading and Delivery
Chen, Z., Yang, S., Liu, X., Gao, Y., Dong, X., Lai, X. P., Zhu, M., Feng, H., Zhu, X., Lu, Q., et al. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c00495 · Cited by 130
Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges
Skotland, T., Iversen, T., Llorente, A., & Sandvig, K. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114326 · Cited by 134
Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors
Kim, J., Cho, H., Lim, D., Joo, M. K., & Kim, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210082 · Cited by 149
Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies
Wei, P.-S., Thota, N., John, G., Chang, E., Lee, S., Wang, Y., Ma, Z., Tsai, Y.-H., & Mei, K. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.030 · Cited by 138
Sustained Drug Release in Nanomedicine: A Long-Acting Nanocarrier-Based Formulation for Glaucoma
Natarajan, J. V., Darwitan, A., Barathi, V. A., Ang, M., Htoon, H. M., Boey, F., Tam, K. C., Wong, T. T. L., & Venkatraman, S. S. (2014) · ACS Nano · doi:10.1021/nn4046024 · Cited by 128
Issues and concerns in nanotech product development and its commercialization
Kaur, I. P., Kakkar, V., Deol, P. K., Yadav, M., Singh, M., & Sharma, I. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.005 · Cited by 128
Smart Nanoscale Drug Delivery Platforms from Stimuli-Responsive Polymers and Liposomes
Lee, S., & Nguyen, S. T. (2013) · Macromolecules · doi:10.1021/ma401529w · Cited by 128
Technical aspects of preparing PEG-PLGA nanoparticles as carrier for chemotherapeutic agents by nanoprecipitation method
Almoustafa, H. A., Alshawsh, M. A., & Chik, Z. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.09.054 · Cited by 132
Mucoadhesive alginate pastes with embedded liposomes for local oral drug delivery
Shtenberg, Y., Goldfeder, M., Prinz, H., Shainsky, J., Ghantous, Y., El‐Naaj, I. A., Schroeder, A., & Bianco‐Peled, H. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.12.137 · Cited by 128
Premature Drug Release from Polyethylene Glycol (PEG)-Coated Liposomal Doxorubicin via Formation of the Membrane Attack Complex
Chen, E., Chen, B., Su, Y.-C., Chang, Y., Cheng, T., Barenholz, Y., & Roffler, S. R. (2020) · ACS Nano · doi:10.1021/acsnano.9b07218 · Cited by 126
Self-citation
Engineering Smart Targeting Nanovesicles and Their Combination with Hydrogels for Controlled Drug Delivery
Elkhoury, K., Koçak, P., Kang, A., Arab‐Tehrany, E., Ward, J. E., & Shin, S. R. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090849 · Cited by 132
Surface modification of nano‐drug delivery systems for enhancing antibiotic delivery and activity
Osman, N., Devnarain, N., Omolo, C. A., Fasiku, V. O., Jaglal, Y., & Govender, T. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1758 · Cited by 136
Cell-based drug delivery systems and their in vivo fate
Yang, L., Yang, Y., Chen, Y., Xu, Y., & Peng, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114394 · Cited by 131
Microfluidic Manufacture of Lipid-Based Nanomedicines
Osouli-Bostanabad, K., Puliga, S., Serrano, D. R., Bucchi, A., Halbert, G., & Lalatsa, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091940 · Cited by 137
Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients
Miao, G., He, Y., Lai, K., Zhao, Y. D., He, P., Tan, G., & Wang, X. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.003 · Cited by 135
Advanced disease therapeutics using engineered living drug delivery systems
Mamidi, N., Silva, F. F. D., & Salehi, A. O. M. (2025) · Nanoscale · doi:10.1039/d4nr05298f · Cited by 132
Cisplatin Prodrug-Conjugated Gold Nanocluster for Fluorescence Imaging and Targeted Therapy of the Breast Cancer
Zhou, F., Feng, B., Yu, H., Wang, D., Wang, T., Liu, J., Meng, Q., Wang, S., Zhang, P., Zhang, Z., et al. (2016) · Theranostics · doi:10.7150/thno.14556 · Cited by 128
Tumor therapy: targeted drug delivery systems
Dai, L., Liu, J., Luo, Z. Y., Li, M., & Cai, K. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb01743f · Cited by 128
Synthesis and Evaluation of Doxorubicin-Loaded Gold Nanoparticles for Tumor-Targeted Drug Delivery
Du, Y., Xia, L., Jo, A., Davis, R. M., Bissel, P., Ehrich, M. F., & Kingston, D. G. I. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00756 · Cited by 127
Bioinspired Multifunctional Melanin-Based Nanoliposome for Photoacoustic/Magnetic Resonance Imaging-Guided Efficient Photothermal Ablation of Cancer
Zhang, L., Sheng, D., Wang, D., Yao, Y., Yang, K., Wang, Z., Deng, L., & Chen, Y. (2018) · Theranostics · doi:10.7150/thno.22430 · Cited by 127
Investigating the EPR effect of nanomedicines in human renal tumors via ex vivo perfusion strategy
Ding, Y., Xu, Y., Yang, W., Niu, P., Li, X., Chen, Y., Li, Z., Liu, Y., An, Y., Liu, Y., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100970 · Cited by 127
Person-Specific Biomolecular Coronas Modulate Nanoparticle Interactions with Immune Cells in Human Blood
Ju, Y., Kelly, H. G., Dagley, L. F., Reynaldi, A., Schlub, T. E., Spall, S. K., Bell, C. A., Cui, J., Mitchell, A. J., Lin, Z., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c06679 · Cited by 128
X-ray-Based Techniques to Study the Nano–Bio Interface
Sánchez-Cano, C., Álvarez‐Puebla, R. A., Abendroth, J. M., Beck, T., Blick, R. H., Cao, Y., Caruso, F., Chakraborty, I., Chapman, H. N., Chen, C., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c09563 · Cited by 128
Protein Nanoparticles: Uniting the Power of Proteins with Engineering Design Approaches
Habibi, N., Mauser, A., Ko, Y., & Lahann, J. (2022) · Advanced Science · doi:10.1002/advs.202104012 · Cited by 130
Nanoliposomes in Cancer Therapy: Marketed Products and Current Clinical Trials
Taléns‐Visconti, R., Dı́ez-Sales, O., de Julián‐Ortiz, J. V., & Nácher, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084249 · Cited by 127
Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics
Leong, E. W. X., & Ge, R. (2022) · Biomedicines · doi:10.3390/biomedicines10092179 · Cited by 134
Can nanomedicines kill cancer stem cells?
Zhao, Y., Alakhova, D. Y., & Kabanov, A. V. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.016 · Cited by 129
Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance
Chen, S., Yang, K., Tuguntaev, R. G., Mozhi, A., Zhang, J., Wang, P. C., & Liang, X. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.10.020 · Cited by 127
New Advances in Nanotechnology-Based Diagnosis and Therapeutics for Breast Cancer: An Assessment of Active-Targeting Inorganic Nanoplatforms
Falagan-Lotsch, P., Grzincic, E. M., & Murphy, C. J. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00591 · Cited by 127
Lipid polymer hybrid nanoparticles as potent vehicles for drug delivery in cancer therapeutics
Parveen, S., Gupta, P., Kumar, S., & Banerjee, M. (2023) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2023.100165 · Cited by 131
Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment
Jin, Y., Huang, Y., Ren, H., Huang, H., Lai, C., Wang, W., Tong, Z., Zhang, H., Wu, W., Liu, C., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2023.122463 · Cited by 130
Novel drug delivery system
Kumar, M., Mandal, U. K., & Mahmood, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91668-4.00012-5 · Cited by 126
A simple way to enhance Doxil® therapy: Drug release from liposomes at the tumor site by amphiphilic block copolymer
Zhao, Y., Alakhova, D. Y., Kim, J. O., Bronich, T. K., & Kabanov, A. V. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.02.026 · Cited by 126
Clinical applications of nanomedicine in cancer therapy
Norouzi, M., Amerian, M., Amerian, M., & Atyabi, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.017 · Cited by 126
Nanomedicine in treatment of breast cancer – A challenge to conventional therapy
Afzal, M., Zafar, A., Alharbi, K. S., Alruwaili, N. K., Al-Abbasi, F. A., Almalki, A. A., Kazmi, I. A., Kumar, V., Kamal, M. A., Nadeem, M. S., et al. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.016 · Cited by 125
The solid progress of nanomedicine
Martins, J. P., das Neves, J., de la Fuente, M., Celia, C., Florindo, H. F., Günday-Türeli, N., Popat, A., Santos, J. L., Sousa, F., Schmid, R., et al. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00743-2 · Cited by 125
A quantitative view on multivalent nanomedicine targeting
Woythe, L., Tito, N. B., & Albertazzi, L. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.11.010 · Cited by 130
Iron oxide-loaded nanotheranostics: major obstacles to in vivo studies and clinical translation
Schleich, N., Danhier, F., & Préat, V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.024 · Cited by 124
Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy
Pérez-Medina, C., Abdel-Atti, D., Tang, J., Zhao, Y., Fayad, Z. A., Lewis, J. S., Mulder, W. J. M., & Reiner, T. (2016) · Nature Communications · doi:10.1038/ncomms11838 · Cited by 128
Crucial factors and emerging concepts in ultrasound-triggered drug delivery
Geers, B., Dewitte, H., Smedt, S. C. D., & Lentacker, I. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.08.014 · Cited by 128
Endocytosis and Organelle Targeting of Nanomedicines in Cancer Therapy
Wang, X., Qiu, Y., Wang, M., Zhang, C.-H., Zhang, T., Zhou, H., Zhao, W., Zhao, W., Xia, G., & Shao, R. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s274289 · Cited by 128
Lipid-based carriers for pulmonary products: Preclinical development and case studies in humans
Cipolla, D. C., Shekunov, B. Y., Blanchard, J., & Hickey, A. J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.001 · Cited by 123
Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy
Fang, R. H., Kroll, A. V., & Zhang, L. (2015) · Small · doi:10.1002/smll.201501284 · Cited by 123
Biomimetic nanoparticle technology for cardiovascular disease detection and treatment
Park, J. H., Dehaini, D., Zhou, J., Holay, M., Fang, R. H., & Zhang, L. (2019) · Nanoscale Horizons · doi:10.1039/c9nh00291j · Cited by 128

Authors: Barenholz, Y. (.
Affiliations: Hebrew University of Jerusalem (IL)
Corresponding author: Barenholz, Yechezkel (Chezy)
ORCID: Barenholz, Yechezkel (Chezy)
Venue: Journal of Controlled Release
Publisher: Elsevier BV
Published: 2012-06
Volume: 160
Issue: 2
Pages: 117-134
ISSN: 0168-3659 (ISSN-L)
DOI: 10.1016/j.jconrel.2012.03.020
OpenAlex: W1989230986
Cited by: 4,792
References: 140
Citations by year: 2026: 415 · 2025: 541 · 2024: 462 · 2023: 405 · 2022: 444 · 2021: 441 · 2020: 436 · 2019: 303 · 2018: 324 · 2017: 284 · 2016: 243 · 2015: 188 · 2014: 174 · 2013: 106 · 2012: 23
FWCI: 8.16
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Controlled Release (publishedVersion)
PubMed (publishedVersion)
Topics: Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords: pegylated liposomal doxorubicin, PEGylated liposomes, nanotherapeutics, doxorubicin, enhanced permeability and retention effect, passive tumor targeting, liposome circulation time, remote loading, phosphatidylcholine, cholesterol, drug release, generic drug availability
MeSH terms: Antibiotics, Antineoplastic, Chemistry, Pharmaceutical, Delayed-Action Preparations, Doxorubicin, Drug Carriers, Drug Compounding, Humans, Liposomes, Solubility, United States, United States Food and Drug Administration, Drug Design, Drug Approval, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Doxil® — The first FDA-approved nano-drug: Lessons learned

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks